<DOC>
	<DOCNO>NCT02017015</DOCNO>
	<brief_summary>The purpose study determine safety efficacy nab-paclitaxel combined gemcitabine Chinese patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Nab-paclitaxel Plus Gemcitabine Chinese Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>This Phase 2 trial China evaluate safety efficacy combination nab-paclitaxel gemcitabine administer patient diagnose metastatic pancreatic adenocarcinoma . This study design Chinese bridge study complement Global pivotal study ( CA-046 ) . The study consist three part : ( 1 ) Dose evaluation ; ( 2 ) Single arm evaluate efficacy follow optimal Simon two-stage design ; ( 3 ) Randomized 2-arm evaluate efficacy safety nab-paclitaxel plus gemcitabine versus gemcitabine alone . These 3 part carry sequentially . The Part 3 randomize 2-arm portion carry deemed necessary per protocol .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patient definitive histologically cytologically confirm metastatic pancreatic adenocarcinoma ( Islet cell neoplasms exclude ) measurable Response Evaluation criterion solid tumor ( RECIST V1.0 ) 2 . Patients must receive previous radiotherapy , surgery , chemotherapy investigational therapy treatment metastatic pancreatic cancer . Prior treatment 5fluorouracil ( 5FU ) gemcitabine administer radiation sensitizer adjuvant setting allow , provide least 6 month elapse since completion last dose linger toxicity present . Patients receive cytotoxic dos gemcitabine chemotherapy adjuvant set eligible study 3 . Patient Karnofsky performance status ( KPS ) ≥ 70 4 . Initial diagnosis metastatic disease must occur ≤ 6 week prior start Cycle 1 Day 1 . NOTE : clock time interval start date last evaluation confirm pancreatic metastatic disease ( either biopsy imaging result ) 5 . Patients asymptomatic jaundice prior Cycle 1 Day 1 . Significant symptomatic amount ascites drain prior Cycle 1 Day 1 . Pain symptom stable require modification analgesic management prior Cycle 1 Day 1 6 . Patient adequate blood count screen ( obtain ≤ 14 day prior start Cycle 1 Day 1 ) : Absolute neutrophil count ( ANC ) ≥ 1.5 × 10^9/L ; Platelet count ≥ 100,000/mm^3 ( 100 × 10^9/L ) ; Hemoglobin ( Hgb ) ≥ 9 g/dL 7 . Patient follow blood chemistry level Screening ( obtain ≤ 14 day prior start Cycle 1 Day 1 ) : Aspartate aminotransferase ( SGOT ) alanine transaminase ( SGPT ) ≤ 2.5 upper limit normal ( ULN ) range , unless liver metastases clearly present , ≤ 5 × upper limit normal ( ULN ) range allow Total bilirubin ≤ upper limit normal range Serum creatinine within normal limit calculate clearance ≥ 60 mL/min/1.73 m^2 patient serum creatinine level institutional normal value . If use creatinine clearance , actual body weight used calculate creatinine clearance ( eg , use CockcroftGault formula ) . For patient body mass index ( BMI ) &gt; 30 kg/m^2 , lean body weight use instead . 8 . The patient acceptable coagulation study ( obtain ≤14 day prior start Cycle 1 Day 1 ) demonstrate prothrombin time ( PT ) partial thromboplastin time ( PTT ) within normal limit ( WNL ) ±15 % . 9 . The patient clinically significant abnormality urinalysis result ( obtained ≤14 day prior start Cycle 1 Day 1 ) . 10 . Male nonpregnant nonlactating female , ≥ 18 year age time sign informed consent document . If female patient childbearing potential , evidence regular menstrual period , must negative pregnancy test ( e.g . serum βsubunit human chorionic gonadotropin ( βhCG ) document prior first administration study drug . If sexually active , patient must agree use contraception consider adequate appropriate Investigator period administration study drug . In addition , male female patient must utilize contraception end treatment recommend product 's 11 . Patient informed nature study , agree participate study , sign Informed Consent Form prior participation studyrelated activity . 12 . Able adhere study visit schedule protocol requirement . 1 . Patient known brain metastasis 2 . Patient locally advance disease . 3 . Patient ≥ 20 % decrease serum albumin level Screening visit within 72 hour prior Cycle 1 Day 1 . 4 . History malignancy last 5 year ( include chronic leukemia ) . Patients prior history situ cancer basal squamous cell skin cancer eligible . Patients malignancy eligible cured surgery alone surgery plus radiotherapy continuously diseasefree least 5 year . 5 . Patient active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . 6 . Patient known infection human immunodeficiency virus , and/or active infection hepatitis B , hepatitis C ( patient know historical infection hepatitis B C discuss Sponsor ) . 7 . Patient undergone major surgery , diagnostic surgery ( ie , surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study . 8 . Patient history myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) Class IIIIV heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia electrocardiogram ( ECG ) abnormality , cerebrovascular accident , transient ischemic attack , seizure disorder clinically significant cardiac dysrhythmia ECG abnormality , within 6 month prior Cycle 1 Day 1 9 . Patient history allergy hypersensitivity study drug excipients , patient exhibit adverse event . 10 . History connective tissue disorder ( eg , lupus , scleroderma , arteritis nodosa ) . 11 . Patients history interstitial lung disease , history slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy . 12 . Patient condition , include serious medical risk factor , medical condition , laboratory abnormality psychiatric disorder , could compromise patient 's safety study data integrity . 13 . Patient enrol clinical protocol investigational trial interventional agent assessment may interfere study procedure . 14 . Patient unwilling unable comply study procedure , plan take vacation 7 consecutive day treatment phase study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pancreatic cancer</keyword>
	<keyword>Metastatic pancreatic cancer</keyword>
	<keyword>treatment pancreatic cancer</keyword>
	<keyword>Abraxane clinical research trial</keyword>
	<keyword>Celgene clinical research trial</keyword>
</DOC>